Payment overview · 2025
General Payments
$168,654.01
149 reported records · 15 companies
Healthcare provider profile · identity verified
Pankit Jaysukh Vachhani, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · BIRMINGHAM, AL · NPI 1982968764
Verified facts
What the public records show
CMS Open Payments records show Pankit Jaysukh Vachhani, MD received $168,654.01 in general payments during 2025 across 149 reported records.
Incyte Corporation accounted for 30.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ayvakit, Jakafi, Ojjaara, Venclexta, Vonjo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Venclexta by this doctor in 2024.
Blueprint Medicines Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AYVAKIT as an associated drug or biological on 4288 records involving 3006 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ayvakit by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AYVAKIT as an associated drug or biological on 4791 records involving 3585 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ayvakit by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OJJAARA as an associated drug or biological on 12602 records involving 5639 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ojjaara by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jakafi by this doctor in 2024.
SOBI, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vonjo as an associated drug or biological on 6568 records involving 3700 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Vonjo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Incyte Corporation | Unresolved — no canonical attribution shown | $51,719.37 | 30.7% | 53 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38,347.57 | 22.7% | 13 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $20,162.00 | 11.9% | 17 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14,655.10 | 8.7% | 7 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $14,611.02 | 8.7% | 6 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8,625.28 | 5.1% | 14 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $8,255.84 | 4.9% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $7,491.87 | 4.4% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $3,620.92 | 2.1% | 8 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $649.90 | 0.4% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $262.27 | 0.2% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $98.91 | 0.1% | 1 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $80.32 | 0.1% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $40.91 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.73 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $87,404.67 | 22 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $54,433.10 | 9 |
| Honoraria | $11,630.00 | 3 |
| Travel and Lodging | $10,617.06 | 44 |
| Food and Beverage | $4,569.18 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $26,232.88 | 23 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $14,611.02 | 6 | 2025 |
Source payment records
|
|||||
| REVUFORJ Normalized: revuforj |
Drug | Syndax Pharmaceuticals, Inc. | $8,383.79 | 12 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $8,255.84 | 5 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological, Drug | Blueprint Medicines Corporation, GENZYME CORPORATION | $4,480.11 | 6 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $2,914.53 | 5 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $2,525.65 | 3 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $448.22 | 5 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $201.68 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $96.46 | 3 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $80.32 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $40.91 | 1 | 2025 |
Source payment records
|
|||||
| BLINCYTO Normalized: blincyto |
Biological | Amgen Inc. | $32.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AYVAKIT ayvakit |
2025 | Ayvakit | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 165 | exact normalized | Medicare Part D |
| OJJAARA ojjaara |
2025 | Ojjaara | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Vonjo vonjo |
2025 | Vonjo | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Blueprint Medicines Corporation Exact reporting entity; no affiliate inference |
2025 | AYVAKIT open payments reported associated product |
CMS Open Payments — General Payments 4288 supporting records · 3006 recipient NPIs · example record 1235804861 |
Ayvakit · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | AYVAKIT open payments reported associated product |
CMS Open Payments — General Payments 4791 supporting records · 3585 recipient NPIs · example record 1233194960 |
Ayvakit · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | OJJAARA open payments reported associated product |
CMS Open Payments — General Payments 12602 supporting records · 5639 recipient NPIs · example record 1190332357 |
Ojjaara · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
165 | 17 |
| SOBI, INC Exact reporting entity; no affiliate inference |
2025 | Vonjo open payments reported associated product |
CMS Open Payments — General Payments 6568 supporting records · 3700 recipient NPIs · example record 1240223698 |
Vonjo · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Jakafi | Ruxolitinib Phosphate | 165 | 17 |
| Hydroxyurea | Hydroxyurea | 107 | 23 |
| Acyclovir | Acyclovir | 90 | 22 |
| Sprycel | Dasatinib | 84 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | 15 |
| Vonjo | Pacritinib Citrate | 41 | suppressed |
| Bosulif | Bosutinib | 39 | suppressed |
| Ayvakit | Avapritinib | 38 | suppressed |
| Venclexta | Venetoclax | 38 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 13 |
| Ojjaara | Momelotinib Dihydrochloride | 31 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 29 | suppressed |
| Gabapentin | Gabapentin | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 22 | suppressed |
| Dasatinib | Dasatinib | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 19 | suppressed |
| Inqovi | Decitabine/Cedazuridine | 17 | suppressed |
| Posaconazole | Posaconazole | 17 | suppressed |
| Tasigna | Nilotinib Hcl | 17 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 12 |
| Promacta | Eltrombopag Olamine | 14 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Tibsovo | Ivosidenib | 12 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $168,654.01 · 149 records | Incyte Corporation | AYVAKIT, BESREMI, BLINCYTO, Doptelet, ICLUSIG, JAKAFI, OJJAARA, REBLOZYL, REVUFORJ, RYTELO, VENCLEXTA, Vonjo, XPOVIO | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ayvakit play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error